Literature DB >> 32309266

Abdominal Pain: A Real Challenge in Novel COVID-19 Infection.

Erika Poggiali1, Pau Mateo Ramos1, Davide Bastoni1, Andrea Vercelli1, Andrea Magnacavallo1.   

Abstract

COVID-19 (coronavirus disease 19) is an infectious disease caused by coronavirus 2019-nCoV. Since its detection in China at the end of 2019, the novel coronavirus has rapidly spread throughout the world and has caused an international public health emergency. The most common manifestation is flu-like symptoms. Mild infections usually improve within a few days, but COVID-19 can cause severe pneumonia with acute respiratory distress syndrome and death. Gastrointestinal symptoms are less common but possible and more difficult to recognize as part of a COVID-19 syndrome. In line with the current opinion of the WHO, we strongly believe that preventive measures and early diagnosis of COVID-19 are crucial to interrupt virus spread and avoid local outbreaks. We report the cases of COVID-19 patients admitted to our Emergency Department who complained of gastrointestinal symptoms at admission. LEARNING POINTS: The novel COVID-19 infection is a severe public health problem which is causing an increasing number of deaths worldwide.Although uncommon, there may be a relationship between gastrointestinal symptoms and COVID-19, as reported in recent studies.Early detection and isolation of patients with COVID-19 infection is the only way to control and limit the global spread of this virus. © EFIM 2020.

Entities:  

Keywords:  COVID-19 infection; abdominal pain; diarrhoea; gastrointestinal symptoms

Year:  2020        PMID: 32309266      PMCID: PMC7162568          DOI: 10.12890/2020_001632

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


INTRODUCTION

The coronaviruses are a large family of viruses that can cause respiratory infections ranging from mild symptoms to severe pneumonia. 2019-nCoV is a new type of coronavirus which was first identified in China. Since its detection in humans at the end of 2019, it has rapidly spread worldwide causing respiratory infections of various degrees of severity. The most common symptoms, which develop within 2–14 days of exposure, are dry cough, fever and fatigue[. Mild infections may be self-limiting in few days, but in some cases the respiratory symptoms can develop into acute respiratory distress syndrome (ARDS) with a high risk of death from multiorgan failure. Nasopharyngeal and oropharyngeal swabs can be used to confirm the presence of 2019-nCoV. A CT scan of the chest is the gold standard for diagnosis and assessment of lung involvement. Ground-glass opacity and crazy-craving patterning are the most common radiological signs of COVID-19 pneumonia. CT is commonly used to evaluate lung damage during recovery[. Recently, we investigated the role of lung US in the early detection of COVID-19 pneumonia and showed a strong correlation between lung US and CT scans in all investigated patients[. No specific treatment or vaccines against COVID-19 are currently available. COVID-19 patients can be treated with antivirals but there is no clear evidence of benefit [. The most important way to fight this viral infection is to detect COVID-19 early, isolate cases, trace contacts and deliver the correct information to the general public [. Gastrointestinal involvement, such as abdominal pain, nausea, vomiting and diarrhoea, has been recently reported in the literature[. Diarrhoea occurs secondary to the interaction between ACE2, highly expressed in the human small intestine, and 2019-nCoV cell entry receptor ACE2. Recent studies show that 2019-nCoV RNA has been detected in stool samples, confirming faecal–oral transmission. According to the literature, the incidence of diarrhoea could be underestimated[. In the current case report, we consider COVID-19 infection in the differential diagnosis of gastrointestinal symptoms in 10 patients who referred to our Emergency Department in February 2020, at the beginning of the spread of COVID-19 in Italy.

CASE DESCRIPTION

Ten patients (6 males, 4 females) with mean age 50±18 years were admitted to our Emergency Department complaining of fever and flu-like symptoms in the previous 5–10 days, with general malaise, decreased appetite, abdominal pain and vomiting/diarrhoea. Only one patient denied cough and fever. None of them had a history of abdominal surgery or a notable medical history, including inflammatory bowel disease. They reported no melena or weight loss. Diarrhoea was defined according the WHO criteria as having three or more loose or liquid stools per day or having more stools than normal. Physical examinations were normal with no distended abdomens, tenderness or hypo/hyperactive bowel sounds. The vital signs were in the normal range with a maximum body temperature of 39°C (37.6±1°C). At admission, four patients complained of dyspnoea with significantly decreased PaO2/FiO2 and a need for oxygen. A nasopharyngeal swab sample confirmed COVID-19 infection in all patients. The patients’ characteristics at admission are reported in Table 1.
Table 1

Patients’ characteristics at admission

Age (years)Sex (M, F)Fever and flu-like symptomsDyspnoeaGIT symptomsBody temperature (°C)PaO2/FiO2 (mmHg)
Pt 144MNoNoDiarrhoea38.7>300
Pt 254FYesNoAbdominal pain39.0>300
Pt 339FYesNoDiarrhoea36.5200
Pt 444MYesYesDiarrhoea38.8>300
Pt 556FYesNoVomiting38.5>300
Pt 657MYesNoDiarrhoea36.9275
Pt 765MYesNoDiarrhoea37.7>300
Pt 822FYesYesDiarrhoea36.8261
Pt 962MYesYesVomiting37.8271
Pt 1055MYesYesVomiting36.0200

F, female; GIT, gastrointestinal; M, male; Pt, patient. Abnormal values are in red.

Laboratory tests revealed lymphopenia, high C-reactive protein and altered liver enzymes in most of the patients, as reported in Table 2. Tests revealed an average white blood cell count (WBC) of 6.15 (3.2–9.29) ×109/l, platelets (PLT) 176.7 (82–341) ×109/l, and lymphocytes 1.31 (0.60–2.76) ×109/l. The eosinophil percentage was undetectable in all patients. The average value of ALT (alanine aminotransferase) was 77.4 U/l (29–162 U/l), AST (aspartate aminotransferase) was 81.9 (30–284) U/l, and GGT (gamma glutamyltransferase) was 123 (54–218) U/l. Bilirubin was increased in only one patient (pt 2, Table 2) who developed pancytopenia and haemolytic anaemia, which improved with oral steroid therapy. The average value of CRP was 6.6 (1.5–21.37) mg/dl. When measured, procalcitonin was always undetectable, excluding a bacterial infection. Despite the diarrhoea, only two patients had slowly increasing creatinine levels (pt 7 and 9, Table 2). The serum potassium level was in the normal range in all patients. In the patient who complained only of diarrhoea with no flu-like symptoms (pt 1, Table 1), we performed stool cultures for Clostridium difficile and enteric pathogens, which were all negative.
Table 2

Laboratory findings at admission

Pt 1Pt 2Pt 3Pt 4Pt 5Pt 6Pt 7Pt 8Pt 9Pt 10
WBC (109/l)9.203.404.034.916.249.855.403.206.049.29
Neutrophil count (109/l)5.731.403.213.283.688.613.542.394.467.43
Lymphocitye count (109/l)2.761.690.601.081.990.941.320.660.861.20
Eosinophil count (109/l)0000000000
PLT count (109/l)14882162168143262150165146341
CRP (<0.5 mg/dl)5.31.546.151.51.196.532.554.0921.3715.85
PCT (>0.5 ng/ml)ND0.03NDNDNDND0.360.02ND0.32
AST (10–37 U/l)1113582294516247958682
ALT (10–37 U/l)1015360304628457676853
GGT (7–40 U/l)13899133NDND549617571218
Total bilirubin (0.1–1.1 mg/dl)0.841.330.630.530.470.790.600.580.710.95
LDH (0–248 U/l)400223634251254343244453594964
Lipase (7–60 U/l)13322614242222416926175
Creatinine (0.6–1.2 mg/dl)1.100.410.681.040.590.941.200.721.251.18
Blood urea nitrogen (10–50 mg/dl)331928NDNDND36214243
Potassium (3.5–5.0 mEq/l)4.34.03.83.53.73.74.33.84.44.4

ALT, alanine transaminase; AST, aspartate transaminase; CRP, C-reactive protein; GGT, gamma glutamyltransferase; ND, not done; PCT, procalcitonin; PLT, platelet; WBC, white blood cell count. Normal range values are in brackets. Abnormal values are in red

All patients were investigated with bedside US, which showed a diffuse B-pattern, due to a severe loss of aeration, with spared areas with no pleural effusion; in six patients subpleural consolidation in the lower lobes was detected. Chest CT confirmed COVID-19 pneumonia with typical imaging signs of ground-glass opacity, patchy consolidation and crazy-paving patterning, which were also detected by lung US. An X-ray of the abdomen was performed in only one patient (pt 2, Table 1) and was normal. US of the abdomen did not reveal an abnormal stomach and bowel distention, except in one female patient (pt 8, Table 1) who had bowel inflammatory signs (peri-intestinal inflammatory reaction) as confirmed by a CT scan of the abdomen. This patient completely recovered after antiviral treatment and was discharged home with no signs of bowel disease on US of the abdomen. All the patients were treated with supportive care and antiviral therapy, including lopinavir and ritonavir tablets. Diarrhoea completely resolved. Six patients have been discharged with the diagnosis of ‘COVID-19 pneumonia and diarrhoea’. Four patients (pt 3, 7, 9, 10, Tables 1 and 2) developed acute severe respiratory distress syndrome requiring immediate intubation. They are still in Intensive Care Unit at the time of writing.

DISCUSSION

Abdominal pain is a real challenge for critical care physicians since there are many potential diagnoses. Signs and symptoms are often non-specific and can mask life-threating conditions. The consequences of wrongly attributing the pain can be serious for patients. Although gastrointestinal symptoms are less common in patients with COVID-19 infection, the diagnosis of coronavirus disease 2019 cannot be excluded and must be investigated in all patients referred to the Emergency Department. We strongly recommend bedside lung US to detect signs of interstitial pneumonia even in absence of respiratory symptoms. Early suspicion and diagnosis are essential to contain the global spread of COVID-19 infection and its potentially fatal complications, such as acute respiratory distress syndrome.
  7 in total

1.  Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus.

Authors:  Weicheng Liang; Zhijie Feng; Shitao Rao; Cuicui Xiao; Xingyang Xue; Zexiao Lin; Qi Zhang; Wei Qi
Journal:  Gut       Date:  2020-02-26       Impact factor: 23.059

2.  SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19.

Authors:  Y Song; P Liu; X L Shi; Y L Chu; J Zhang; J Xia; X Z Gao; T Qu; M Y Wang
Journal:  Gut       Date:  2020-03-05       Impact factor: 23.059

3.  Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19).

Authors:  Feng Pan; Tianhe Ye; Peng Sun; Shan Gui; Bo Liang; Lingli Li; Dandan Zheng; Jiazheng Wang; Richard L Hesketh; Lian Yang; Chuansheng Zheng
Journal:  Radiology       Date:  2020-02-13       Impact factor: 11.105

4.  Can Lung US Help Critical Care Clinicians in the Early Diagnosis of Novel Coronavirus (COVID-19) Pneumonia?

Authors:  Erika Poggiali; Alessandro Dacrema; Davide Bastoni; Valentina Tinelli; Elena Demichele; Pau Mateo Ramos; Teodoro Marcianò; Matteo Silva; Andrea Vercelli; Andrea Magnacavallo
Journal:  Radiology       Date:  2020-03-13       Impact factor: 11.105

5.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

6.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

7.  A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

Authors:  Bin Cao; Yeming Wang; Danning Wen; Wen Liu; Jingli Wang; Guohui Fan; Lianguo Ruan; Bin Song; Yanping Cai; Ming Wei; Xingwang Li; Jiaan Xia; Nanshan Chen; Jie Xiang; Ting Yu; Tao Bai; Xuelei Xie; Li Zhang; Caihong Li; Ye Yuan; Hua Chen; Huadong Li; Hanping Huang; Shengjing Tu; Fengyun Gong; Ying Liu; Yuan Wei; Chongya Dong; Fei Zhou; Xiaoying Gu; Jiuyang Xu; Zhibo Liu; Yi Zhang; Hui Li; Lianhan Shang; Ke Wang; Kunxia Li; Xia Zhou; Xuan Dong; Zhaohui Qu; Sixia Lu; Xujuan Hu; Shunan Ruan; Shanshan Luo; Jing Wu; Lu Peng; Fang Cheng; Lihong Pan; Jun Zou; Chunmin Jia; Juan Wang; Xia Liu; Shuzhen Wang; Xudong Wu; Qin Ge; Jing He; Haiyan Zhan; Fang Qiu; Li Guo; Chaolin Huang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Dingyu Zhang; Chen Wang
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

  7 in total
  11 in total

1.  RESULTS OF SURGICAL TREATMENT OF COLORECTAL CANCER, ELECTIVE AND EMERGENCY, IN PATIENTS WITH COVID-19.

Authors:  Sergio Carlos Nahas; José Donizeti de Meira Júnior; Caio Sergio Rizkallah Nahas; Lucas Faraco Sobrado; Rodrigo Ambar Pinto; Edson Abdala; Ulysses Ribeiro Junior; Ivan Cecconello
Journal:  Arq Bras Cir Dig       Date:  2022-06-17

2.  Triage decision-making at the time of COVID-19 infection: the Piacenza strategy.

Authors:  Poggiali Erika; Vercelli Andrea; Maria Grazia Cillis; Eva Ioannilli; Teresa Iannicelli; Magnacavallo Andrea
Journal:  Intern Emerg Med       Date:  2020-05-09       Impact factor: 3.397

3.  Proximal femur fractures in COVID-19 emergency: the experience of two Orthopedics and Traumatology Departments in the first eight weeks of the Italian epidemic.

Authors:  Pietro Maniscalco; Erika Poggiali; Fabrizio Quattrini; Corrado Ciatti; Andrea Magnacavallo; Andrea Vercelli; Marco Domenichini; Enrico Vaienti; Francesco Pogliacomi; Francesco Ceccarelli
Journal:  Acta Biomed       Date:  2020-05-11

Review 4.  Pain in Covid Era.

Authors:  Heloísa Alonso-Matielo; Victória Regina da Silva Oliveira; Victhor Teixeira de Oliveira; Camila Squarzoni Dale
Journal:  Front Physiol       Date:  2021-02-02       Impact factor: 4.566

Review 5.  Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases.

Authors:  Md Abdul Barek; Md Abdul Aziz; Mohammad Safiqul Islam
Journal:  Heliyon       Date:  2020-12-15

6.  Gastroenterology manifestations and COVID-19 outcomes: A meta-analysis of 25,252 cohorts among the first and second waves.

Authors:  Rami M Elshazli; Adam Kline; Abdelaziz Elgaml; Mohamed H Aboutaleb; Mohamed M Salim; Mahmoud Omar; Ruhul Munshi; Nicholas Mankowski; Mohammad H Hussein; Abdallah S Attia; Eman A Toraih; Ahmad Settin; Mary Killackey; Manal S Fawzy; Emad Kandil
Journal:  J Med Virol       Date:  2021-02-23       Impact factor: 20.693

Review 7.  COVID-19: clinical issues from the Japan Surgical Society.

Authors:  Masaki Mori; Norihiko Ikeda; Akinobu Taketomi; Yo Asahi; Yoshio Takesue; Tatsuya Orimo; Minoru Ono; Takashi Kuwayama; Seigo Nakamura; Yohei Yamada; Tatsuo Kuroda; Kenji Yuzawa; Taizo Hibi; Hiroaki Nagano; Michiaki Unno; Yuko Kitagawa
Journal:  Surg Today       Date:  2020-07-11       Impact factor: 2.549

8.  Abdominal imaging findings on computed tomography in patients acutely infected with SARS-CoV-2: what are the findings?

Authors:  Michio Taya; Viktoriya Paroder; Gil Redelman-Sidi; Natalie Gangai; Jennifer S Golia Pernicka; Marc J Gollub; Sidra Javed-Tayyab; Iva Petkovska; David D B Bates
Journal:  Emerg Radiol       Date:  2021-10-03

9.  A Systematic Review of Abdominal Imaging Findings in COVID-19 Patients.

Authors:  Priya Singh; Surya Pratap Singh; Amit Kumar Verma; Sreenivasa Narayana Raju; Anit Parihar
Journal:  Visc Med       Date:  2021-08-26

10.  The eyes see what the mind seeks: a systematic review of abdominal imaging findings in patients with COVID-19.

Authors:  Lokesh Agarwal; Ayushi Agarwal; Shailesh Advani; Varidh Katiyar; Aprajita Chaturvedi; Kumble Seetharama Madhusudhan
Journal:  Br J Radiol       Date:  2021-07-14       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.